Towards Healthcare

Cell and Gene Therapy Tools and Reagents Companies and Innovation and Product Evolution

Date : 14 October 2025

Which are the Top Companies in the Market?

Cell and Gene Therapy Tools and Reagents Market Companies

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Lonza Group
  • Miltenyi Biotec 
  • Bio-Rad Laboratories
  • Takara Bio Inc.
  • Agilent Technologies
  • QIAGEN N.V.
  • Sartorius AG
  • Danaher Corporation
  • PerkinElmer Inc.
  • GenScript Biotech
  • Corning Incorporated
  • Oxford Biomedica
  • Charles River Laboratories

Market Forecast

The global cell and gene therapy tools and reagents market size is calculated at US$ 10.04 billion in 2024, grew to US$ 11.12 billion in 2025, and is projected to reach around US$ 27.3 billion by 2034. The market is expanding at a CAGR of 10.76% between 2025 and 2034.

Growing CGT Developments: There is a rise in cell and gene therapy development, which is increasing the demand for suitable tools and reagents. Thus, new collaborations among the companies and institutes are being formed to leverage their tools and reagents. Moreover, there is a growth in investments and funding to enhance the development of reagents, tools, and therapies.

For instance,

  • In August 2025, a collaboration between Sartorius Stedim Biotech and Nanotein Technologies was formed, where 3 million US dollars was invested by Sartorius to enhance the development and commercialization of solutions based on its NanoSpark® platform. The reagents, such as NanoSpark® GROW-NK Soluble Activator and NanoSpark® STEM-T Soluble T Cell Activator, will be distributed by Sartorius to customers worldwide, which will be used in the NK-based cancer therapies and CAR-T therapies.
  • In March 2025, to support the development and commercialisation of an investigational gene therapy that is AAV-GAD, developed by MeiraGTx for Parkinson’s disease, funding of around $430m was offered by Hologen. To completely finance the programme, $200m upfront and $230m in additional capital will be provided by the AI company.

Market Value Chain Analysis

R&D

The R&D of cell and gene therapy tools and reagents includes enhancing and developing materials, technologies, and processes to improve the scalability, safety, and efficacy of the therapies.

Key Players: Thermo Fisher Scientific, Sartorius AG, Danaher Corporation, Merck KGaA, Charles River, Lonza Group, WuXi AppTec.

Packaging and Serialization

The packaging and serialization of cell and gene therapy tools and reagents focus on developing containers with maintained ultralow temperature, contamination protection, and unique tracking identifiers to ensure regulatory compliance, secure chain of custody, and product integrity.

Key Players: Marken, Cryoport, DHL Supply Chain and FedEx, World Courier

Distribution to Hospitals, Pharmacies

The distribution to hospitals and pharmacies of cell and gene therapy tools and reagents involves the use of cold chain logistics or direct manufacturer-to-hospitals shipments with a secure chain of identity and ultra-low temperature deliveries to the designated healthcare centres.

Key Players: Marken, Cryoport, DHL Supply Chain and FedEx, World Courier

Patient Support and Services

Comprehensive assistance, such as emotional support, financial navigation, logistic coordination, and educational resources, will be provided to the patients in the patient support and services of the cell and gene therapy tools and reagents.

Key Players: Bluebird Bio, Novartis Gene Therapies, Vertex Pharmaceuticals

Latest Announcements by Industry Leaders

In January 2025, after announcing the collaboration between CTMC and Syenex, the CEO of CTMC, Jason Bock, said that, to amplify the supply of transformative cell therapies to patients is their mission. Their fast access to the increasing suite of validated technologies is being expanded by introducing advanced systems of Syenex in the lentiviral and retroviral vector manufacturing platforms of CTMC. Thus, to address the critical challenges in efficiency and scalability, comprehensive technical solutions will be provided by this integration to their biotech partners.

What are the Recent Developments in the Market?

  • In January 2025, a first-in-class cell manufacturing transfection media product, that is CellFE T-Rest, for resting (quiescent) T cell workflows, was launched by CellFE. For developing safer and potent therapies, the product helps in optimizing the gene editing workflow that utilizes resting T cells as a starting material.
  • In September 2024, a comprehensive suite of tools, that is the AAV Edge System, was launched by Asimov for the design and manufacturing of adeno-associated viral (AAV) gene therapy. To enhance gene therapy development, the tool will provide the gene therapy developer with a single access point to an array of best-in-class tools.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com